Latest From InnerPulse Inc.
Boston Scientific’s S-ICD subcutaneous implantable cardioverter defibrillator performed well in the EFFORTLESS registry, with clinical event rates and inappropriate shock rates similar to those reported for conventional ICDs in a real-world context.
A percutaneous intravascular cardioverter-defibrillator matched a conventional ICD in a randomized comparison of defibrillation thresholds. The authors of the study believe the PICD could reduce many of the complications associated with conventional defibrillators.
- Implantable Devices
- Therapeutic Areas
- Interventional Rhythm Management Inc.
- North America
- Parent & Subsidiaries
- InnerPulse Inc.
- Senior Management
Daniel A Pelak, Pres. & CEO
Benny Ward, VP, CFO
James F Buck, VP, Mktg. & Bus. Dev.
Terry Ransbury, VP, R&D
W. Eugene Sanders, Jr., MD, VP, Medical Affairs & CMO
- Contact Info
Research Triangle Park, NC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.